Canine diabetes Variable criteria for categorizing diabetes types may play a great part. Knowledgeable patient participation is vital and so patient education is a crucial aspect of this effort. Most of this difference is not currently understood. Canine diabetes. Cancer survivors who received allogenic Hematopoeitic Cell Transplantation (HCT) are 3.65 times more likely to report type 2 diabetes than their siblings. These include cardiovascular disease (doubled risk), chronic renal failure (the main cause of dialysis in developed world adults), retinal damage (which can lead to blindness and is the most significant cause of adult blindness in the non-elderly in the developed world), nerve damage (of several kinds), microvascular damage (including erectile dysfunction (impotence) and poor healing which can lead to gangrene and even amputation -- the leading cause of non-traumatic amputation in developed world adults). Insulin enables most body cells (about 2/3 is the usual estimate, including muscle cells and adipose tissue) to absorb glucose from the blood for use as fuel, for conversion to other needed molecules, or for storage. The most useful laboratory test to distinguish Type 1 from Type 2 diabetes is the C-peptide assay, which is a measure of endogenous insulin production since external insulin to date has included no C-peptide. Many patients with type 2 diabetes will progress to insulin therapy to control of blood glucose levels, but these patients are still type 2 diabetics. The most important forms of diabetes are characterized by decreases in, or the plete absence of, the production of insulin (Type 1 diabetes), or decreased sensitivity of body tissues to insulin (type 2 diabetes). Diabetes mellitus is a metabolic disorder characterized by hyperglycemia (high glucose blood sugar), among other signs. Lack of insulin resistance, determined by a glucose tolerance test, would also be suggestive of Type 1. The adult incidence of Type 1 is similar to that for children [1], which is one of the reasons for changing the preferred term. Stem cell research has also been suggested as a potential avenue for a cure since it may permit the regrowth of islet cells which are geically part of the treated individual, thus eliminating the need for immuno-suppressants. Zanosar is the trade name for streptozotocin, an antibiotic and antineoplastic agent used in chemotherapy for pancreatic cancer, that kills beta cells, resulting in loss of insulin production. The adult incidence of Type 1 is similar to that for children [1], which is one of the reasons for changing the preferred term. |